Plain-English translation of NCT07205887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new eye medication called given as injections directly into the eye to treat two types of vision loss: age-related macular degeneration (a disease affecting the center of the retina as people age) and swelling in the macula caused by a blocked blood vessel in the eye. The study will test two different dose levels of the medication to see which works better and how safe it is.
Age-related macular degeneration and blocked blood vessels in the eye can cause serious vision loss, and some patients don't respond well to current treatments. This trial is testing whether this new medication—either alone or combined with an existing treatment—can help more people maintain or improve their vision.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive three injections of the medication into your study eye, spaced four weeks apart. You will visit the clinic at injection visits and additional follow-up visits every 2 to 4 weeks, depending on which group you are in, for a total of 12 weeks. At each visit, your eye will be examined with specialized imaging and tests to measure your vision and check how well the treatment is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States